Department of Investigative Medicine, Hammersmith Hospital, Imperial College London, 6th Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK.
Peptides. 2011 Nov;32(11):2290-4. doi: 10.1016/j.peptides.2011.07.021. Epub 2011 Jul 30.
Ghrelin is a peptide hormone secreted into circulation from the stomach. It has been postulated to act as a signal of hunger. Ghrelin administration acutely increases energy intake in lean and obese humans and chronically induces weight gain and adiposity in rodents. Circulating ghrelin levels are elevated by fasting and suppressed following a meal. Inhibiting ghrelin signaling therefore appears an attractive target for anti-obesity therapies. A number of different approaches to inhibiting the ghrelin system to treat obesity have been explored. Despite this, over a decade after its discovery, no ghrelin based anti-obesity therapies are close to reaching the market. This article discusses the role of ghrelin in appetite control in humans, examines different approaches to inhibiting the ghrelin system and assesses their potential as anti-obesity therapies.
胃泌素是一种从胃分泌到循环系统中的肽类激素。它被认为是饥饿的信号。胃泌素给药可在瘦人和肥胖人群中急性增加能量摄入,并在啮齿动物中慢性诱导体重增加和肥胖。禁食会升高循环胃泌素水平,而餐后会抑制其分泌。因此,抑制胃泌素信号似乎是治疗肥胖症的一种有吸引力的靶点。为了治疗肥胖症,人们已经探索了许多不同的抑制胃泌素系统的方法。尽管如此,在发现胃泌素十多年后,还没有基于胃泌素的抗肥胖疗法接近上市。本文讨论了胃泌素在人类食欲控制中的作用,考察了抑制胃泌素系统的不同方法,并评估了它们作为抗肥胖疗法的潜力。